Prevalence and clinical significance of potential drug–drug interaction in hematopoietic stem cell transplantation
- 27 December 2014
- journal article
- Published by Springer Nature in Cancer Chemotherapy and Pharmacology
- Vol. 75 (2) , 393-400
Abstract
Patients undergoing hematopoietic stem cell transplantation (HSCT) are at risk of developing potential drug–drug interactions (PDDIs). The aim of this study was to assess the prevalence of PDDIs that occur in HSCT patients on the day of hematopoietic stem cell infusion. We performed a cross-sectional study based on the evaluation of prescriptions to HSCT patients on the day of infusion (day 0). The PDDIs were analyzed using the DRUG-REAX® system and classified according to the severity level, available scientific evidence, time of onset, and potential clinical impact. Forty patients undergoing HSCT were included in this study; 33 patients (82.5 %) were exposed to at least one major and one contraindicated PDDI in a concomitant manner. All patients exposed to PDDIs had an increased risk of cardiotoxicity. Most cases of PDDIs were classified as being of major severity (80.9 %), with time of onset not specified (61.9 %), and with good or excellent scientific evidence (52.4 %). HSCT patients have a high prevalence of clinically significant PDDIs. The management of PDDIs requires an approach that includes biochemical tests, installation of cardiac monitors, periodic electrocardiograms, implementation of electronic prescriptions with a PDDI alert system, and availability of the PDDI databases.Keywords
This publication has 33 references indexed in Scilit:
- Potential drug–drug interactions at a referral hematology–oncology ward in Iran: a cross-sectional studyCancer Chemotherapy and Pharmacology, 2013
- Risk Factors and Drug Interactions Predisposing to Statin-Induced MyopathyDrug Safety, 2010
- Tiering Drug-Drug Interaction Alerts by Severity Increases Compliance RatesJournal of the American Medical Informatics Association, 2009
- Patients at High Risk of Invasive Fungal InfectionsDrugs, 2008
- Potential Drug Interactions and Duplicate Prescriptions Among Cancer PatientsJNCI: Journal of the National Cancer Institute, 2007
- Drug interactions in cancer therapyNature Reviews Cancer, 2006
- Rhabdomyolysis associated with hydroxymethylglutaryl-coenzyme A reductase inhibitorsAmerican Heart Journal, 2004
- Antiemetic guidelines: creating a more practical treatment approachSupportive Care in Cancer, 2002
- 5-HT3-Receptor Antagonists and the Cytochrome P450 SystemThe Cancer Journal, 2002
- TropisetronDrugs, 1992